Tolerability and efficacy of vortioxetine versus SSRIs in elderly with major depression. Study protocol of the VESPA study: a pragmatic, multicentre, open-label, parallel-group, superiority, randomized trial

Giovanni Ostuzzi, Chiara Gastaldon, Angelo Barbato, Barbara D'Avanzo, Mauro Tettamanti, Igor Monti, Andrea Aguglia, Eugenio Aguglia, Maria Chiara Alessi, Mario Amore, Francesco Bartoli, Massimo Biondi, Paola Bortolaso, Camilla Callegari, Giuseppe Carrà, Rosangela Caruso, Simone Cavallotti, Cristina Crocamo, Armando D'Agostino, Pasquale De Fazio, Chiara Di Natale, Laura Giusti, Luigi Grassi, Giovanni Martinotti, Michela Nosé, Davide Papola, Marianna Purgato, Alessandro Rodolico, Rita Roncone, Lorenzo Tarsitani, Giulia Turrini, Elisa Zanini, Francesco Amaddeo, Mirella Ruggeri, Corrado Barbui, Giovanni Ostuzzi, Chiara Gastaldon, Angelo Barbato, Barbara D'Avanzo, Mauro Tettamanti, Igor Monti, Andrea Aguglia, Eugenio Aguglia, Maria Chiara Alessi, Mario Amore, Francesco Bartoli, Massimo Biondi, Paola Bortolaso, Camilla Callegari, Giuseppe Carrà, Rosangela Caruso, Simone Cavallotti, Cristina Crocamo, Armando D'Agostino, Pasquale De Fazio, Chiara Di Natale, Laura Giusti, Luigi Grassi, Giovanni Martinotti, Michela Nosé, Davide Papola, Marianna Purgato, Alessandro Rodolico, Rita Roncone, Lorenzo Tarsitani, Giulia Turrini, Elisa Zanini, Francesco Amaddeo, Mirella Ruggeri, Corrado Barbui

Abstract

Introduction: Depression is a highly prevalent condition in the elderly, with a vast impact on quality of life, life expectancy, and medical outcomes. Selective serotonin reuptake inhibitors (SSRIs) are the most commonly prescribed agents in this condition and, although generally safe, tolerability issues cannot be overlooked. Vortioxetine is an antidepressant with a novel mechanism of action. Based on studies to date, it may have a promising tolerability profile in the elderly, as it does not adversely affect psychomotor or cognitive performance and does not alter cardiovascular and endocrine parameters. The present study aims to assess the tolerability profile of vortioxetine in comparison with the SSRIs considered as a single group in elderly participants with depression. The rate of participants withdrawing from treatment due to adverse events after 6 months of follow up will be the primary outcome.

Methods and analysis: This is a pragmatic, multicentre, open-label, parallel-group, superiority, randomized trial funded by the Italian Medicines Agency (AIFA - Agenzia Italiana del Farmaco). Thirteen Italian Community Psychiatric Services will consecutively enrol elderly participants suffering from an episode of major depression over a period of 12 months. Participants will be assessed at baseline and after 1, 3 and 6 months of follow up. At each time point, the following validated rating scales will be administered: Montgomery-Åsberg Depression Rating Scale (MADRS), Antidepressant Side-Effect Checklist (ASEC), EuroQual 5 Dimensions (EQ-5D), Short Blessed Test (SBT), and Charlson Age-Comorbidity Index (CACI). Outcome assessors and the statistician will be masked to treatment allocation. A total of 358 participants (179 in each group) will be enrolled.

Ethics and dissemination: This study will fully adhere to the ICH E6 Guideline for Good Clinical Practice. Participants' data will be managed and safeguarded according to the European Data Protection Regulation 2016/679. An external Ethical Advisory Board will help guarantee high ethical standards.

Trial registration: Clinicaltrials.gov: NCT03779789 , Registered on 19 December 2018. Submitted on 19 December. EudraCT number: 2018-001444-66.

Trial status: Protocol version 1.5; 09/06/2018. Recruitment started In February 2019 and it is ongoing. It is expected to end approximately on 30 September 2021.

Keywords: Antidepressants; Depression; Elderly; Pragmatic trial; Randomized clinical trial; Vortioxetine.

Conflict of interest statement

The authors have no competing interests to disclose.

Figures

FIg. 1
FIg. 1
SPIRIT figure
Fig. 2
Fig. 2
Study flow-chart. SSRI, selective serotonin reuptake inhibitor
Fig. 3
Fig. 3
Pragmatism wheel according to the Pragmatic–explanatory continuum indicator summary-2 (PRECIS-2) tool

References

    1. GBD Global, regional, and national comparative risk assessment of 79 behavioural, environmental and occupational, and metabolic risks or clusters of risks, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet. 2016;388(10053):1659–1724. doi: 10.1016/s0140-6736(16)31679-8.
    1. Centers for Disease Control and Prevention (CDCP) Current depression among adults-United States, 2006 and 2008. Morb Mortal Wkly Rep. 2010;59(38):1229–1235.
    1. Ames D. Depression among elderly residents of local-authority residential homes. Its nature and the efficacy of intervention. Br J Psychiatry. 1990;156:667–675. doi: 10.1192/bjp.156.5.667.
    1. Eden J. The mental health and substance use workforce for older adults. In whose hands? Washington D.C: National Academies Press; 2012.
    1. Heisel MJ, Grek A, Moore SL, Jackson F, Vincent G. National guidelines for seniors’ mental health: the assessment of suicide risk and prevention of suicide. Can J Geriatr. 2006;9(2):s65–s70.
    1. Steenland K, Karnes C, Seals R, Carnevale C, Hermida A, Levey A. Late-life depression as a risk factor for mild cognitive impairment or Alzheimer’s disease in 30 US Alzheimer’s disease centers. J Alzheimers Dis. 2012;31(2):265–275. doi: 10.3233/jad-2012-111922.
    1. Jiang W, Alexander J, Christopher E, Kuchibhatla M, Gaulden LH, Cuffe MS, Blazing MA, Davenport C, Califf RM, Krishnan RR, O'Connor CM. Relationship of depression to increased risk of mortality and rehospitalization in patients with congestive heart failure. Arch Intern Med. 2001;161(15):1849–1856. doi: 10.1001/archinte.161.15.1849.
    1. National Institute for Health and Care Excellence (Great Britain). NICE. Depression in adults: recognition and management (Clinical guideline cg 90). Updated 2016. Retrieved form: . Accessed May 2020.
    1. Cipriani A, Furukawa TA, Salanti G, Chaimani A, Atkinson LZ, Ogawa Y, Leucht S, Ruhe HG, Turner EH, Higgins JPT, Egger M, Takeshima N, Hayasaka Y, Imai H, Shinohara K, Tajika A, Ioannidis JPA, Geddes JR. Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis. Lancet. 2018;391(10128):1357–1366. doi: 10.1016/s0140-6736(17)32802-7.
    1. Mezuk B, Edwards L, Lohman M, Choi M, Lapane K. Depression and frailty in later life: a synthetic review. Int J Geriatr Psychiatry. 2012;27(9):879–892. doi: 10.1002/gps.2807.
    1. Taylor WD. Should antidepressant medication be used in the elderly? Expert Rev Neurother. 2015;15(9):961–963. doi: 10.1586/14737175.2015.1070671.
    1. Sultana J, Spina E, Trifiro G. Antidepressant use in the elderly: the role of pharmacodynamics and pharmacokinetics in drug safety. Expert Opin Drug Metab Toxicol. 2015;11(6):883–892. doi: 10.1517/17425255.2015.1021684.
    1. Mottram P, Wilson K, Strobl J. Antidepressants for depressed elderly. Cochrane Database Syst Rev. 2006;(1):Cd003491. 10.1002/14651858.CD003491.pub2.
    1. Avasthi A, Grover S. Clinical practice guidelines for management of depression in elderly. Indian J Psychiatry. 2018;60(Suppl 3):S341–Ss62. doi: 10.4103/0019-5545.224474.
    1. de Abajo FJ. Effects of selective serotonin reuptake inhibitors on platelet function: mechanisms, clinical outcomes and implications for use in elderly patients. Drugs Aging. 2011;28(5):345–367. doi: 10.2165/11589340-000000000-00000.
    1. Hickie IB. Antidepressants in elderly people. BMJ. 2011;343:d4660. doi: 10.1136/bmj.d4660.
    1. Mallery L, MacLeod T, Allen M, McLean-Veysey P, Rodney-Cail N, Bezanson E, Steeves B, LeBlanc C, Moorhouse P. Systematic review and meta-analysis of second-generation antidepressants for the treatment of older adults with depression: questionable benefit and considerations for frailty. BMC Geriatr. 2019;19(1):306. doi: 10.1186/s12877-019-1327-4.
    1. FDA. Drug approval package. Brintellix (vortioxetine) Tablets. Company: Takeda Pharmaceuticals USA, Inc.; Application No.: 204447. USA: Food and Drug Adminstration; 2013.
    1. EMA. Brintellix. Vortioxetine. Procedure No. EMEA/H/C/002717. Applicant: H. Lundbeck A/S. Assessment report for an initial marketing authorisation application. Europe: European Medicines Agency; 2013.
    1. Stahl SM. Modes and nodes explain the mechanism of action of vortioxetine, a multimodal agent (MMA): enhancing serotonin release by combining serotonin (5HT) transporter inhibition with actions at 5HT receptors (5HT1A, 5HT1B, 5HT1D, 5HT7 receptors) CNS Spectr. 2015;20(2):93–97. doi: 10.1017/s1092852915000139.
    1. EMA. Brintellix: EPAR - Product information. Brintellix -EMEA/H/C/002717 -IB/0020. European Medicines Agency. . 2014.
    1. Yang KC, Stepanov V, Amini N, Martinsson S, Takano A, Bundgaard C, Bang-Andersen B, Sanchez C, Halldin C, Farde L, Finnema SJ. Effect of clinically relevant doses of vortioxetine and citalopram on serotonergic PET markers in the nonhuman primate brain. Neuropsychopharmacology. 2019;44(10):1706–1713. doi: 10.1038/s41386-019-0442-4.
    1. Gonda X, Sharma SR, Tarazi FI. Vortioxetine: a novel antidepressant for the treatment of major depressive disorder. Expert Opin Drug Discov. 2019;14(1):81–89. doi: 10.1080/17460441.2019.1546691.
    1. Methodology WCCfDS. Oslo: ATC classification index with DDDs; 2019.
    1. Kelliny M, Croarkin PE, Moore KM, Bobo WV. Profile of vortioxetine in the treatment of major depressive disorder: an overview of the primary and secondary literature. Ther Clin Risk Manag. 2015;11:1193–1212. doi: 10.2147/tcrm.S55313.
    1. McIntyre RS, Lophaven S, Olsen CK. A randomized, double-blind, placebo-controlled study of vortioxetine on cognitive function in depressed adults. Int J Neuropsychopharmacol. 2014;17(10):1557–1567. doi: 10.1017/s1461145714000546.
    1. Miskowiak KW, Ott CV, Petersen JZ, Kessing LV. Systematic review of randomized controlled trials of candidate treatments for cognitive impairment in depression and methodological challenges in the field. Eur Neuropsychopharmacol. 2016;26(12):1845–1867. doi: 10.1016/j.euroneuro.2016.09.641.
    1. Koesters M, Ostuzzi G, Guaiana G, Breilmann J, Barbui C. Vortioxetine for depression in adults. Cochrane Database Syst Rev. 2017;7:Cd011520. doi: 10.1002/14651858.CD011520.pub2.
    1. Krause M, Gutsmiedl K, Bighelli I, Schneider-Thoma J, Chaimani A, Leucht S. Efficacy and tolerability of pharmacological and non-pharmacological interventions in older patients with major depressive disorder: a systematic review, pairwise and network meta-analysis. Eur Neuropsychopharmacol. 2019;29(9):1003–1022. doi: 10.1016/j.euroneuro.2019.07.130.
    1. Baune BT, Sluth LB, Olsen CK. The effects of vortioxetine on cognitive performance in working patients with major depressive disorder: a short-term, randomized, double-blind, exploratory study. J Affect Disord. 2018;229:421–428. doi: 10.1016/j.jad.2017.12.056.
    1. Vieta E, Sluth LB, Olsen CK. The effects of vortioxetine on cognitive dysfunction in patients with inadequate response to current antidepressants in major depressive disorder: a short-term, randomized, double-blind, exploratory study versus escitalopram. J Affect Disord. 2018;227:803–809. doi: 10.1016/j.jad.2017.11.053.
    1. Katona C, Hansen T, Olsen CK. A randomized, double-blind, placebo-controlled, duloxetine-referenced, fixed-dose study comparing the efficacy and safety of Lu AA21004 in elderly patients with major depressive disorder. Int Clin Psychopharmacol. 2012;27(4):215–223. doi: 10.1097/YIC.0b013e3283542457.
    1. Orimo H. Reviewing the definition of elderly. Nihon Ronen Igakkai Zasshi. 2006;43(1):27–34. doi: 10.3143/geriatrics.43.27.
    1. Ford I, Norrie J. Pragmatic trials. N Engl J Med. 2016;375(5):454–463. doi: 10.1056/NEJMra1510059.
    1. Zwarenstein M, Treweek S, Gagnier JJ, Altman DG, Tunis S, Haynes B, Oxman AD, Moher D. Improving the reporting of pragmatic trials: an extension of the CONSORT statement. BMJ. 2008;337:a2390. doi: 10.1136/bmj.a2390.
    1. Chan AW, Tetzlaff JM, Altman DG, Laupacis A, Gotzsche PC, Krleza-Jeric K, Hrobjartsson A, Mann H, Dickersin K, Berlin JA, Dore CJ, Parulekar WR, Summerskill WS, Groves T, Schulz KF, Sox HC, Rockhold FW, Rennie D, Moher D. SPIRIT 2013 statement: defining standard protocol items for clinical trials. Ann Intern Med. 2013;158(3):200–207. doi: 10.7326/0003-4819-158-3-201302050-00583.
    1. Loudon K, Treweek S, Sullivan F, Donnan P, Thorpe KE, Zwarenstein M. The PRECIS-2 tool: designing trials that are fit for purpose. BMJ. 2015;350:h2147. doi: 10.1136/bmj.h2147.
    1. Dal-Re R, Janiaud P, Ioannidis JPA. Real-world evidence: how pragmatic are randomized controlled trials labeled as pragmatic? BMC Med. 2018;16(1):49. doi: 10.1186/s12916-018-1038-2.
    1. EU Directive 2010/84/EU of the European Parliament and of the Council of 15 December 2010 amending, as regards pharmacovigilance, Directive 2001/83/EC on the Community code relating to medicinal products for human use. Off J Eur Comm. 2010;348:74–99.
    1. EU Communication from the Commission — detailed guidance on the collection, verification and presentation of adverse event/reaction reports arising from clinical trials on medicinal products for human use (‘CT-3’) Off J Eur Union. 2011;2011/C(172):1–13.
    1. Barbui C, Furukawa TA, Cipriani A. Effectiveness of paroxetine in the treatment of acute major depression in adults: a systematic re-examination of published and unpublished data from randomized trials. CMAJ. 2008;178(3):296–305. doi: 10.1503/cmaj.070693.
    1. Wang S, Blazer DG. Depression and cognition in the elderly. Annu Rev Clin Psychol. 2015;11:331–360. doi: 10.1146/annurev-clinpsy-032814-112828.
    1. Okolie C, Dennis M, Simon Thomas E, John A. A systematic review of interventions to prevent suicidal behaviors and reduce suicidal ideation in older people. Int Psychogeriatr. 2017;29(11):1801–1824. doi: 10.1017/s1041610217001430.
    1. Higgins JPT, Green S. Cochrane handbook for systematic reviews of interventions version 5.1.0 [updated March 2011]. UK: The Cochrane Collaboration; 2011.
    1. Uher R, Farmer A, Henigsberg N, Rietschel M, Mors O, Maier W, Kozel D, Hauser J, Souery D, Placentino A, Strohmaier J, Perroud N, Zobel A, Rajewska-Rager A, Dernovsek MZ, Larsen ER, Kalember P, Giovannini C, Barreto M, McGuffin P, Aitchison KJ. Adverse reactions to antidepressants. Br J Psychiatry. 2009;195(3):202–210. doi: 10.1192/bjp.bp.108.061960.
    1. Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry. 1979;134:382–389. doi: 10.1192/bjp.134.4.382.
    1. Nierenberg AA, DeCecco LM. Definitions of antidepressant treatment response, remission, nonresponse, partial response, and other relevant outcomes: a focus on treatment-resistant depression. J Clin Psychiatry. 2001;62(Suppl 16):5–9.
    1. Hammond MF. Rating depression severity in the elderly physically ill patient: reliability and factor structure of the Hamilton and the Montgomery-Asberg Depression Rating Scales. Int J Geriatr Psychiatry. 1998;13(4):257–261. doi: 10.1002/(sici)1099-1166(199804)13:4<257::aid-gps773>;2-u.
    1. EuroQol EuroQol--a new facility for the measurement of health-related quality of life. Health Policy. 1990;16(3):199–208. doi: 10.1016/0168-8510(90)90421-9.
    1. McCaffrey N, Kaambwa B, Currow DC, Ratcliffe J. Health-related quality of life measured using the EQ-5D-5L: South Australian population norms. Health Qual Life Outcomes. 2016;14(1):133. doi: 10.1186/s12955-016-0537-0.
    1. Katzman R, Brown T, Fuld P, Peck A, Schechter R, Schimmel H. Validation of a short Orientation-Memory-Concentration Test of cognitive impairment. Am J Psychiatry. 1983;140(6):734–739. doi: 10.1176/ajp.140.6.734.
    1. Charlson M, Szatrowski TP, Peterson J, Gold J. Validation of a combined comorbidity index. J Clin Epidemiol. 1994;47(11):1245–1251. doi: 10.1016/0895-4356(94)90129-5.
    1. EU. Directive 2001/20/EC of the European Parliament and of the Council of 4 April 2001 on the approximation of the laws, regulations and administrative provisions of the Member States relating to the implementation of good clinical practice in the conduct of clinical trials on medicinal products for human use, 2001.
    1. Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data capture (REDCap)--a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform. 2009;42(2):377–381. doi: 10.1016/j.jbi.2008.08.010.
    1. Wilkinson MD, Dumontier M, Aalbersberg IJ, Appleton G, Axton M, Baak A, Blomberg N, Boiten JW, da Silva Santos LB, Bourne PE, Bouwman J, Brookes AJ, Clark T, Crosas M, Dillo I, Dumon O, Edmunds S, Evelo CT, Finkers R, Gonzalez-Beltran A, Gray AJ, Groth P, Goble C, Grethe JS, Heringa J, Hoen PA, Hooft R, Kuhn T, Kok R, Kok J, Lusher SJ, Martone ME, Mons A, Packer AL, Persson B, Rocca-Serra P, Roos M, van Schaik R, Sansone SA, Schultes E, Sengstag T, Slater T, Strawn G, Swertz MA, Thompson M, van der Lei J, van Mulligen E, Velterop J, Waagmeester A, Wittenburg P, Wolstencroft K, Zhao J, Mons B. The FAIR Guiding principles for scientific data management and stewardship. Sci Data. 2016;3:160018. doi: 10.1038/sdata.2016.18.
    1. Mahableshwarkar AR, Zajecka J, Jacobson W, Chen Y, Keefe RS. A randomized, placebo-controlled, active-reference, double-blind, flexible-dose study of the efficacy of vortioxetine on cognitive function in major depressive disorder. Neuropsychopharmacology. 2015;40(8):2025–2037. doi: 10.1038/npp.2015.52.
    1. Pocock SJ. Clinical trials. A practical approach. Chichester: Wiley; 1983.
    1. Little RJ, D'Agostino R, Cohen ML, Dickersin K, Emerson SS, Farrar JT, Frangakis C, Hogan JW, Molenberghs G, Murphy SA, Neaton JD, Rotnitzky A, Scharfstein D, Shih WJ, Siegel JP, Stern H. The prevention and treatment of missing data in clinical trials. N Engl J Med. 2012;367(14):1355–1360. doi: 10.1056/NEJMsr1203730.
    1. Zou G. A modified poisson regression approach to prospective studies with binary data. Am J Epidemiol. 2004;159(7):702–706. doi: 10.1093/aje/kwh090.
    1. Stata Statistical Software: Release 15 [program]. College Station: StataCorp LLC, 2017.
    1. WMA World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA. 2013;310(20):2191–2194. doi: 10.1001/jama.2013.281053.
    1. EU Regulation (EU) 2016/679 of the European Parliament and of the COUNCIL of 27 April 2016 on the protection of natural persons with regard to the processing of personal data and on the free movement of such data, and repealing Directive 95/46/EC (General Data Protection Regulation) Off J Eur Union. 2016;119:1–88.

Source: PubMed

Sponzoři a spolupracovníci

Zdravotní podmínky

Drogové intervence

3
Předplatit